{"protocolSection":{"identificationModule":{"nctId":"NCT06602193","orgStudyIdInfo":{"id":"DNLI-C-0009"},"organization":{"fullName":"Denali Therapeutics Inc.","class":"INDUSTRY"},"briefTitle":"Safety and Pharmacodynamic Effects of BIIB122 in Participants With LRRK2-Associated Parkinson's Disease (LRRK2-PD)","officialTitle":"A Phase 2a, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Pharmacodynamic Effects of BIIB122 in Participants With LRRK2-Associated Parkinson's Disease (LRRK2-PD)"},"statusModule":{"statusVerifiedDate":"2026-02","overallStatus":"RECRUITING","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2024-10-24","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2026-04-30","type":"ESTIMATED"},"completionDateStruct":{"date":"2028-02-28","type":"ESTIMATED"},"studyFirstSubmitDate":"2024-09-16","studyFirstSubmitQcDate":"2024-09-16","studyFirstPostDateStruct":{"date":"2024-09-19","type":"ACTUAL"},"lastUpdateSubmitDate":"2026-02-16","lastUpdatePostDateStruct":{"date":"2026-02-18","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Denali Therapeutics Inc.","class":"INDUSTRY"},"collaborators":[{"name":"Biogen","class":"INDUSTRY"}]},"oversightModule":{"isFdaRegulatedDrug":true,"isFdaRegulatedDevice":false},"descriptionModule":{"briefSummary":"This Phase 2a, multicenter, randomized, 12-week double-blind, placebo-controlled, parallel-group study, followed by an OLE, is designed to evaluate the safety, tolerability, and pharmacodynamic effects of BIIB122 in participants with LRRK2-PD. LRRK2-PD is defined as Parkinson's Disease (PD) in individuals who are heterozygous or homozygous carriers of a pathogenic LRRK2 variant that increases LRRK2 kinase activity."},"conditionsModule":{"conditions":["Parkinson Disease"],"keywords":["LRRK2","Movement Disorders"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE2"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"DOUBLE","whoMasked":["PARTICIPANT","INVESTIGATOR"]}},"enrollmentInfo":{"count":50,"type":"ESTIMATED"}},"armsInterventionsModule":{"armGroups":[{"label":"BIIB122 225 mg","type":"EXPERIMENTAL","description":"Oral 225 mg dose, once daily (QD)","interventionNames":["Drug: BIIB122 225 mg"]},{"label":"BIIB122 Matching Placebo","type":"PLACEBO_COMPARATOR","description":"Oral BIIB122 matching placebo, once daily (QD)","interventionNames":["Other: BIIB122-Matching Placebo"]}],"interventions":[{"type":"DRUG","name":"BIIB122 225 mg","description":"Administered as specified in the treatment arm","armGroupLabels":["BIIB122 225 mg"],"otherNames":["DNL151"]},{"type":"OTHER","name":"BIIB122-Matching Placebo","description":"Administered as specified in the treatment arm","armGroupLabels":["BIIB122 Matching Placebo"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Incidence of treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs) with BIIB122 compared with placebo over the 12-week double-blind period","timeFrame":"12 weeks"}],"secondaryOutcomes":[{"measure":"Change from baseline in whole-blood pS935 LRRK2 with BIIB122 compared with placebo at Week 12","timeFrame":"12 weeks"},{"measure":"Change from baseline in urine BMP with BIIB122 compared with placebo at Week 12","timeFrame":"12 weeks"}],"otherOutcomes":[{"measure":"Incidence of TEAEs and SAEs during the OLE period","timeFrame":"2.5 years"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* For heterozygous pathogenic LRRK2 mutation carriers: ≥ 30 to ≤ 80 years\n* For homozygous pathogenic LRRK2 mutation carriers: ≥ 30 years\n* Have screening genetic test results verifying the presence of a pathogenic LRRK2 variant.\n* Have a clinical diagnosis of PD meeting the Movement Disorder Society Clinical Diagnostic Criteria.\n\nExclusion Criteria:\n\n* Have a history of any clinically significant neurological disorder other than PD, including, but not limited to, stroke and dementia, in the opinion of the investigator, within 5 years of the screening visit.\n* Have clinical evidence of atypical parkinsonism (eg, multiple-system atrophy or progressive supranuclear palsy) or evidence of drug-induced parkinsonism.\n* Have previously participated or are currently participating in the BIIB122 LUMA study (Study 283PD201).\n* Have previously participated or are currently participating in a gene therapy study for PD.\n* Have a history of brain surgical intervention for PD (eg, deep-brain stimulation, pallidotomy).\n* Have any physical condition that may confound the motor assessment (MDS-UPDRS) over time (eg, severe arthritis, severe dyskinesias, traumatic injuries with permanent physical disability).\n* Abnormal vitals including Blood Pressure, Heart Rate, or Body Temperature\n* Have abnormal PFT results at screening\n\nNote: Other protocol defined Inclusion/Exclusion criteria may apply","healthyVolunteers":false,"sex":"ALL","minimumAge":"30 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"centralContacts":[{"name":"Clinical Trials at Denali Therapeutics","role":"CONTACT","email":"clinical-trials@dnli.com"}],"overallOfficials":[{"name":"Danna Jennings, MD","affiliation":"Denali Therapeutics","role":"STUDY_DIRECTOR"}],"locations":[{"facility":"Cedars-Sinai Department of Neurology","status":"RECRUITING","city":"Los Angeles","state":"California","zip":"90048","country":"United States","contacts":[{"name":"Anne Tran","role":"CONTACT","phone":"310-423-1697","email":"anne.tran@cshs.org"},{"name":"Michele Tagliati, MD","role":"PRINCIPAL_INVESTIGATOR"}],"geoPoint":{"lat":34.05223,"lon":-118.24368}},{"facility":"University of California San Francisco","status":"RECRUITING","city":"San Francisco","state":"California","zip":"94158","country":"United States","contacts":[{"name":"Luisa Bolo Dave","role":"CONTACT","email":"Luisa.Bolodave@ucsf.edu"},{"name":"Marta San Luciano Palenzuela, MD","role":"PRINCIPAL_INVESTIGATOR"}],"geoPoint":{"lat":37.77493,"lon":-122.41942}},{"facility":"Parkinson's Disease and Movement Disorders Center","status":"RECRUITING","city":"Boca Raton","state":"Florida","zip":"33486","country":"United States","contacts":[{"name":"Stuart Isaacson, MD","role":"CONTACT","phone":"561-392-1818","email":"info@ParkinsonsCenter.org"},{"name":"Stuart Isaacson, MD","role":"PRINCIPAL_INVESTIGATOR"}],"geoPoint":{"lat":26.35869,"lon":-80.0831}},{"facility":"Beth Israel Deaconess Medical Center","status":"RECRUITING","city":"Boston","state":"Massachusetts","zip":"02215","country":"United States","contacts":[{"name":"Jackie Forbes","role":"CONTACT","phone":"617-667-9885","email":"jforbes1@bidmc.harvard.edu"},{"name":"Ludy Shih, MD","role":"PRINCIPAL_INVESTIGATOR"}],"geoPoint":{"lat":42.35843,"lon":-71.05977}},{"facility":"Ichan School of Medicine at Mount Sinai/Beth Israel Downtown-Movement Disorder Center","status":"RECRUITING","city":"New York","state":"New York","zip":"10003","country":"United States","contacts":[{"name":"Ricardo Renvill","role":"CONTACT","phone":"212-844-6055","email":"Ricardo.Renvill@mountsinai.org"},{"name":"Matthew Swan, MD","role":"PRINCIPAL_INVESTIGATOR"}],"geoPoint":{"lat":40.71427,"lon":-74.00597}},{"facility":"Evergreen Health Laboratory","status":"RECRUITING","city":"Kirkland","state":"Washington","zip":"98034","country":"United States","contacts":[{"name":"EvergreenHealth Research Department","role":"CONTACT","email":"EvergreenResearch@evergreenhealthcare.org"},{"name":"Pinky Agarwal, MD","role":"PRINCIPAL_INVESTIGATOR"}],"geoPoint":{"lat":47.68149,"lon":-122.20874}},{"facility":"Inland Northwest Research","status":"RECRUITING","city":"Spokane","state":"Washington","zip":"99202","country":"United States","contacts":[{"name":"Jason Aldred, MD","role":"CONTACT","phone":"509-960-2818","email":"jaldred@selkirkneurology.com"},{"name":"Jason Aldred, MD","role":"PRINCIPAL_INVESTIGATOR"}],"geoPoint":{"lat":47.65966,"lon":-117.42908}},{"facility":"Technische Universität Dresden","status":"RECRUITING","city":"Dresden","country":"Germany","contacts":[{"name":"Marian Kollaske","role":"CONTACT","email":"Marian.Kollaske@ukdd.de"},{"name":"Björn Falkenburger, MD","role":"PRINCIPAL_INVESTIGATOR"}],"geoPoint":{"lat":51.05089,"lon":13.73832}},{"facility":"University of Lübeck","status":"RECRUITING","city":"Lübeck","country":"Germany","contacts":[{"name":"Madita Grümmer","role":"CONTACT","email":"madita.gruemmer@uni-luebeck.de"},{"name":"Norbert Brüggemann, MD","role":"PRINCIPAL_INVESTIGATOR"}],"geoPoint":{"lat":53.86893,"lon":10.68729}},{"facility":"University Hospital Tübingen","status":"RECRUITING","city":"Tübingen","country":"Germany","contacts":[{"name":"Susanne Solbrig","role":"CONTACT","email":"Susanne.Solbrig@med.uni-tuebingen.de"},{"name":"Thomas Gasser, MD","role":"PRINCIPAL_INVESTIGATOR"}],"geoPoint":{"lat":48.52266,"lon":9.05222}},{"facility":"Rabin Medical Center","status":"RECRUITING","city":"Petah Tikva","country":"Israel","contacts":[{"name":"Dana Vhava","role":"CONTACT","email":"danavh@clalit.org.il"},{"name":"Ruth Djaldetti, MD","role":"PRINCIPAL_INVESTIGATOR"}],"geoPoint":{"lat":32.08707,"lon":34.88747}},{"facility":"Movement Disorders Institute, Sheba Medical Center","status":"RECRUITING","city":"Ramat Gan","country":"Israel","contacts":[{"name":"Adi Saar","role":"CONTACT","email":"adi.saar@sheba.health.gov.il"},{"name":"Sharon Hassin, MD","role":"PRINCIPAL_INVESTIGATOR"}],"geoPoint":{"lat":32.08227,"lon":34.81065}},{"facility":"Tel Aviv Medical Center","status":"RECRUITING","city":"Tel Aviv","country":"Israel","contacts":[{"name":"Adi Ezra","role":"CONTACT","email":"adil@tlvmc.gov.il"},{"name":"Tanya Gurevich, MD","role":"PRINCIPAL_INVESTIGATOR"}],"geoPoint":{"lat":32.08088,"lon":34.78057}},{"facility":"Hospital Clinic de Barcelona","status":"RECRUITING","city":"Barcelona","country":"Spain","contacts":[{"name":"Pilar Santacruz","role":"CONTACT","email":"PSANTA@clinic.cat"},{"name":"Alicia Garrido, MD","role":"PRINCIPAL_INVESTIGATOR"}],"geoPoint":{"lat":41.38879,"lon":2.15899}},{"facility":"Hospital Universitari General de Catalunya","status":"RECRUITING","city":"Barcelona","country":"Spain","contacts":[{"name":"Susana Andrade","role":"CONTACT","phone":"+3493175715","email":"s.andrade@udic.es"},{"name":"Ernest Balaguer Martínez, MD","role":"PRINCIPAL_INVESTIGATOR"}],"geoPoint":{"lat":41.38879,"lon":2.15899}},{"facility":"Hospital Universitari Vall d'Hebron","status":"RECRUITING","city":"Barcelona","country":"Spain","contacts":[{"name":"Alejandra Garcia Blanco","role":"CONTACT","email":"alejandra.garcia@vhir.org"},{"name":"Jorge Hernandez-Vara, MD","role":"PRINCIPAL_INVESTIGATOR"}],"geoPoint":{"lat":41.38879,"lon":2.15899}},{"facility":"Hospital Universitario Donostia","status":"RECRUITING","city":"Donostia / San Sebastian","country":"Spain","contacts":[{"name":"Ioana Croitoru","role":"CONTACT","email":"ioana.croitoru@bio-gipuzkoa.eus"},{"name":"Javier Ruiz Martinez, MD","role":"PRINCIPAL_INVESTIGATOR"}],"geoPoint":{"lat":43.31283,"lon":-1.97499}},{"facility":"Universitary Hospital La Princesa","status":"RECRUITING","city":"Madrid","country":"Spain","contacts":[{"name":"Pablo Sáinz-Ezquerra","role":"CONTACT","email":"p.sainzezquerra@gmail.com"},{"name":"Lydia Lopez-Manzares, MD","role":"PRINCIPAL_INVESTIGATOR"}],"geoPoint":{"lat":40.4165,"lon":-3.70256}},{"facility":"IDIVAL/University Hospital Marques de Valdecilla","status":"RECRUITING","city":"Santander","country":"Spain","contacts":[{"name":"Raquel Martinez","role":"CONTACT","email":"raquel.martinez@scsalud.es"},{"name":"Jon Infante, MD","role":"PRINCIPAL_INVESTIGATOR"}],"geoPoint":{"lat":43.46589,"lon":-3.80493}},{"facility":"Hospital Universitario Virgen del Rocio","status":"RECRUITING","city":"Seville","country":"Spain","contacts":[{"name":"Cristina Gomez Rapela","role":"CONTACT","email":"cgomez-ibis@us.es"},{"name":"Lorena Garrote","role":"CONTACT","email":"lgarrote-ibis@us.es"},{"name":"Pablo Mir Rivera, MD","role":"PRINCIPAL_INVESTIGATOR"}],"geoPoint":{"lat":37.38283,"lon":-5.97317}}]},"ipdSharingStatementModule":{"ipdSharing":"NO"}},"derivedSection":{"miscInfoModule":{"versionHolder":"2026-02-25"},"conditionBrowseModule":{"meshes":[{"id":"D010300","term":"Parkinson Disease"},{"id":"D009069","term":"Movement Disorders"}],"ancestors":[{"id":"D020734","term":"Parkinsonian Disorders"},{"id":"D001480","term":"Basal Ganglia Diseases"},{"id":"D001927","term":"Brain Diseases"},{"id":"D002493","term":"Central Nervous System Diseases"},{"id":"D009422","term":"Nervous System Diseases"},{"id":"D000080874","term":"Synucleinopathies"},{"id":"D019636","term":"Neurodegenerative Diseases"}]},"interventionBrowseModule":{"meshes":[{"id":"C000730636","term":"DNL151"}]}},"hasResults":false}